Sanofi Takes Options on Oxford Biomedica's Gene Therapies
LONDON – Oxford Biomedica plc said that Sanofi SA is taking up its options on two gene therapy products for treating retinal disease, triggering a $3 million milestone and providing the impetus for a placing and open offer to raise up to £16 million (US$25 million).
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5476
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST